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Abstract
Granulomas may develop as a response to a local antigenic trigger, leading to the activation of macrophages and T-lymphocytes. Primary
immunodeﬁciency (PID) is associated with the development of extensive cutaneous granulomas, whose aetiology remains unknown. We
performed high-throughput sequencing of the transcriptome of cutaneous granuloma lesions on two consecutive index cases, and RT-PCR
in a third consecutive patient. The RA27/3 vaccine strain of rubella virus—the core component of a universally used paediatric vaccine—was
present in the cutaneous granuloma of these three consecutive PID patients. Controls included the healthy skin of two patients,
non-granulomatous cutaneous lesions of patients with immunodeﬁciency, and skin biopsy samples of healthy individuals, and were negative.
Expression of viral antigens was conﬁrmed by immunoﬂuorescence. Persistence of the rubella vaccine virus was also demonstrated in
granuloma lesions sampled 4–5 years earlier. The persistence of the rubella virus vaccine strain in all three consecutive cutaneous
granuloma patients with PID strongly suggests a causal relationship between rubella virus and granuloma in this setting.
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Introduction
Primary immunodeﬁciency (PID) leads to increased suscep-
tibility to infections. Granuloma is a histopathological term
that deﬁnes a polymorphic inﬂammatory inﬁltrate with a
predominance of macrophages. According to its organization
and the presence of necrosis, various types of granuloma
have been described, which are associated with infections
such as mycobacteriosis, and inﬂammatory diseases such as
sarcoidosis [1]. Granulomas may develop in adults with
primary immunodeﬁciency, such as common variable immu-
nodeﬁciency. In contrast, <50 cases of cutaneous granuloma
in paediatric PID patients have been reported so far, only as
short series [2,3] or case reports [4] in patients with T-cell
immunodeﬁciencies such as Rag deﬁciencies, cartilage hair
hypoplasia [3], and ataxia telangiectasia (AT) [5]. AT is a
recessive autosomal condition caused by loss of function
mutations of the ATM gene, which encodes a protein kinase
that plays a major role in the repair of dsDNA breaks. AT is
characterized by developmental abnormalities, neurodegen-
erative disease, combined immunodeﬁciency, and a predispo-
sition to malignancies. In the context of AT, skin granuloma is
evocative of an underlying opportunistic infection, but
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prolonged, broad-spectrum antimicrobial therapy has never
led, in our experience and to our knowledge, to any
improvement. Moreover, repeated microbial cultures and
targeted PCR for uncultivable bacteria or viruses of skin
samples have always given negative results ([2] and our
unpublished results).
In order to identify putative infectious agents associated
with cutaneous granuloma in the context of PID, we subjected
cutaneous skin biopsy samples to high-throughput sequencing
(HTS). This method consists of sequencing all of the RNAs of a
biological sample and sorting these millions of short reads to
identify sequences of DNA and RNA viruses, bacteria, fungi,
and parasites. Its fundamental advantage is high sensitivity
without any a priori targets [6].
To our surprise, in three children with PID and cutaneous
granuloma who we investigated, we consecutively detected
sequences corresponding to a strain similar to the rubella virus
(RV) vaccine Wistar RA 27/3 strain and different from the
current circulating genotypes. Its presence was conﬁrmed by
RT-PCR and immunohistology. Healthy skin of two available
index patients with granulomas and control skin samples of
immunodeﬁcient patients without granuloma and immuno-
competent individuals with or without granuloma were all
negative. These results indicate that the RV RA 27/3 vaccine
strain persists in the skin of patients with PID, and that this
persistence may favour the development of granuloma in the
context of PID.
Materials and Methods
Case reports
Patient 1 was a 9-year-old girl with AT. Cutaneous nodules
occurred on the buttocks at around the age of 18 months, and
later spread to the limbs, trunk, and face. A skin biopsy
performed at the age of 3 years conﬁrmed the diagnosis of
granuloma, with sarcoidosic, indifferent and lepromatous
features according to Ackerman’s classiﬁcation [1]. The
inﬂammatory inﬁltrate was polymorphic with a predominance
of histiocytes and a minor population of lymphocytes, mostly
CD8+. No infectious agent was identiﬁed by culture or PCR. A
clinical and genetic diagnosis of AT was made at the age of
4 years, because of AT clinical features and immunodeﬁciency
with undetectable plasma levels of IgG and IgA (<0.36 g/L and
<0.06 g/L, respectively), normal plasma levels of IgM (0.42 g/L),
and mild lymphopenia (1290 lymphocytes/mm3) with a low
count of naive CD4+ T-lymphocytes. Immunoglobulin replace-
ment therapy was started, in association with sulphamethox-
azole–trimethoprim and azithromycin prophylaxis. The patient
received iterative antibiotic treatments for severe interstitial
chronic pneumonia, and her clinical status deteriorated
progressively. A new skin biopsy was performed at the age
of 9 years, with the same ﬁndings of intricate granuloma types
(Fig. 1a–c), and the sample was subjected to HTS. In the
following months, the patient was diagnosed with diffuse large
B-cell lymphoma.
Patient 2 was a 15-year-old boy with molecularly conﬁrmed
Simpson–Golabi–Behmel syndrome, an X-linked condition
that is caused in some patients, including this one, by
mutations in the glypican 3 gene, which is involved in the
regulation of cell proliferation [7]. The phenotype is variable,
and is characterized by developmental abnormalities. In this
patient, these were associated with a complex immune
disorder consisting of combined immunodeﬁciency, lympho-
proliferation (pulmonary lymphoid inﬁltration), and autoim-
munity (anaemia). At 14 months of age, he developed
recurrent pneumonia and severe virus-associated conditions
(chickenpox, herpes simplex, and molluscum contagiosum) in a
context of protracted lymphoproliferation. At the age of
11 years, he developed eruptive granuloma, involving the
buttocks and limbs, and then the face and trunk. Investigations
showed 3800 circulating lymphocytes/mm3, with 1600
T-lymphocytes (1000 CD4+ and 600 CD8+), polyclonal
hypergammaglobulinaemia (IgG level of 16.8 g/L, a normal
IgA level (1.52 g/L), and elevated IgM plasma levels (3.2 g/L))
with selective IgG2 deﬁciency and altered anti-polysaccharide
antibody responses. Treatment consisted of immunoglobulin
replacement therapy, and antimicrobial prophylaxis with
penicillin, sulphamethoxazole–thrimethoprim, and sirolimus.
A skin biopsy conﬁrmed the diagnosis of granuloma (indiffer-
ent and non-sarcoidosis type). The cellular population was
polymorphic, consisting essentially of histiocytes, with a minor
lymphocyte population, mostly CD8+. No infectious agent was
identiﬁed by culture or PCR. At the age of 14 years, a new
skin biopsy sample showing a similar granuloma (Fig. 1d–f) was
subjected to HTS, and a 2-mm-diameter biopsy was per-
formed in healthy skin.
Patient 3 was a 5-year-old girl with AT. She developed
severe recurrent pneumonia from the age of 6 months, severe
chickenpox at 2 years of age, hepatosplenomegaly, and,
progressively, ocular telangiectasia and cerebellar ataxia.
Treatment consisted of immunoglobulin replacement, and
sulphamethoxazole–trimethoprim antimicrobial prophylaxis.
Cutaneous granulomas occurred on the knees and elbows at
the age of 33 months, spreading progressively to the limbs and
buttocks. They consisted of annular, erythemato-squamous
papular lesions with atrophic centres and well-limited inﬁl-
trated borders. Skin biopsies were performed at the age of
5 years, and conﬁrmed the diagnosis of granuloma, with a
polymorphic inﬁltrate (histiocytes and lymphocytes, mostly
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CD8+). The coexistence of different types of granuloma was
remarkable: undeﬁned granuloma in the upper dermis, sarc-
oidal granuloma in the middle dermis, and palisading granuloma
in the deep dermis. A 2-mm-diameter biopsy was performed in
healthy skin. The characteristics of the immunodeﬁciency were
as follows: an IgG level of 1.49 g/L, an IgA level of 1.12 g/L, and
a very high IgM plasma level (14.1 g/L); and 980 lymphocytes/
mm3, with low counts of CD4+, naive CD4+, CD8+ and naive
CD8+ T-lymphocytes and an absence of proliferation after
stimulation with candidin and tetanus toxin. The a-fetoprotein
level was elevated, at 55.6 lg/L.
Study design
Skin biopsy samples of patient 1 (sample code 110292) and
patient 2 (120479) (index cases) were subjected to HTS
analysis independently. On the basis of the initial results,
another case (patient 3) was included, and additional samples
from these patients were analysed with RT-PCR for speciﬁc
target ampliﬁcation, including lymphomatous lymph node
biopsy samples, earlier skin biopsy samples, and biopsy samples
from healthy skin that could be obtained from patients 2 and 3
(Table 1). As controls, skin biopsy samples from ﬁve additional
patients were also studied: (i) three from patients with
(a)
(b)
(c)
(d)
(e)
(f)
(g)
(h)
(i)
FIG. 1. Clinical cases. Patient 1. (a) Macroscopic aspect of granuloma. (b) Cutaneous granuloma biopsy tissue section, haematein eosin; 950
magniﬁcation. Granulomatous inﬁltration in an undeﬁned pattern affecting the deep dermis and subcutis. Small, well-limited non-necrotic granulomas
are present. (c) Detail of a sarcoidosic granuloma: nodule composed of epithelioid histiocytes (arrow), with lymphocytes around it; 9400
magniﬁcation. Patient 2. (d) Inﬁltrated erythematous plaques. (e) Cutaneous granuloma biopsy tissue section, haematein eosin; 9100 magniﬁcation.
Granulomatous inﬁltration of the dermis in an undeﬁned pattern, particularly located around pilo-sebaceous adnexae, composed of lymphocytes and
histiocytes. They are arranged in poorly limited tuberculoid granulomas. (f) Inﬁltration in sweat glands, with some histiocytes. Some of them are
epithelioid (arrow), and associated with giant cells (arrowhead); 9400 magniﬁcation. Patient 3. (g) Annular lesion with a well-limited inﬁltrated
border and a hyperkeratotic atrophic centre. (h) Skin biopsy: haematein eosin; 950 magniﬁcation. Coexistence of undeﬁned granulomas in the upper
dermis and sarcoidal granuloma in the middle dermis. (i) Skin biopsy: haematein eosin; 9100 was the best magniﬁcation for observing the coexistence
of sarcoidal granuloma in the middle dermis and palisading granulomas in the deep dermis.
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immunodeﬁciency showing non-granulomatous skin lesions, in
the context of dyskeratosis congenita with severe active
chronic skin graft-versus-host disease (patient 4), unclassiﬁed
combined immunodeﬁciency with severe eczematous erythro-
derma (patient 5), and acquired immunodeﬁciency with ver-
ruquous cutaneous lesion of chronic chickenpox (patient 6);
and (ii) two from patients without immunodeﬁciency, managed
for nevus resection with excision limits in healthy skin and
normal skin controls (patients 7 and 8). All patients had been
vaccinated with a live rubella vaccine during their ﬁrst year of
life (Table 1). All patients or parents of children gave written
informed consent for the use of these samples, which were
used in conformity with French legislation.
HTS and bioinformatics analysis
Total RNA was extracted from biopsy samples or slide
sections in TRIzol (Life Technologies, Saint Aubin, France),
using for biopsies only a FastPrep system (MP Biomedicals,
Santa Ana, CA, USA), and puriﬁed with a QiagenMinelute spin
column treated with DNase I (Qiagen, Valencia, CA, USA) to
digest genomic DNA, as recommended. cDNA synthesis was
performed with random hexamers and Superscript III reverse
transcriptase (Invitrogen, Saint Aubin, France). Ligation of
cDNA, nucleic acid ampliﬁcation by the bacteriophage Phi29
polymerase, sequencing and bioinformatics analysis were
performed as previously described [8]. Reads were generated
on an Illumina HiSeq-2000 sequencer (GATC Biotech AG,
Konstanz, Germany) with a sequencing depth of 80 9 106 and
148 9 106 paired-end reads of 101 nucleotides for patients 1
and 2, respectively.Sequences were trimmed and ﬁltered
according to their quality score. After human genome
sequence subtraction (from NCBI build 37.1/assembly hg19)
with SOAPaligner and BlastN, reads were assembled in contigs
by CLC Genomics (Cambridge, MA, USA), and contigs and
singletons were assigned a given taxonomy by use of the
nucleotidic and proteic Blast algorithm, with e-values of,
respectively, 103 and 10.
RV detection by RT-PCR and strain typing
Total RNA was reverse transcribed with random primers
(patients 1 and 2) or primer Ru1R [9] (patient 3) and
Superscript III reverse transcriptase, and digested with
RNase H according to the manufacturer’s instructions (Invi-
trogen). For RV E1 gene ampliﬁcation, two primers, Ru4f and
Ru3r [9], were used to generate an 860-nucleotide fragment
(nucleotides 8687–9546; GenBank accession number L78917)
covering the 739-nucleotide minimum window recommended
by the WHO for genotyping (nucleotides 8731–9469) [10]. A
second pair of primers, 8669F and SPR8 [11] (nucleo-
tides 8669–9112), that only partially covered the739 nucle-
otides was used when the previous primer pair failed to
amplify.
TABLE 1. Samples, clinical settings, and RT-PCR results
Patient condition Birthdate, rubella vaccination Sex
Sampling
date
Ru4f/Ru3r
PCR
8669F/SPR8
PCR
Granulomatous lesions of the skin associated with immunodeﬁciency
Patient 1 (915 U 18 001): ataxia telangiectasia 13 October 2002, Priorix
(20 February 2004)
F
Granuloma biopsy (110292)* 11 May 2011 Positive Positive
Granuloma biopsy (P9) 3 May 2006 Negative Positive
Lymph node biopsy (P8) 28 September 2011 Negative Positive
Plasma 11 May 2011 Negative Negative
Serum 11 May 2011 Negative Negative
Patient 2 (915 U 18 002): Simpson–Golabi–Behmel syndrome 21 February 1997, R0R VAX (13 March
1998), Priorix (21 September 2002
M
Granuloma biopsy (120479)* 15 February 2012 Positive Positive
Healthy skin biopsy (P6) 15 May 2013 Negative Negative
Granuloma biopsy (P5) 23 January 2008 Negative Positive
Plasma 15 February 2012 Negative Negative
Patient 3 (915 U 18 011): ataxia telangiectasia 15 June 2008 F
Granuloma biopsy (S-13-0089) MMRvaxProR (18 November 2009) 22 May 2013 Negative Positive
Healthy skin biopsy (S-13-0088) MMRvaxProR (11 October 2010) 22 May 2013 Negative Negative
Non-granulomatous lesions of the skin with immunodeﬁciency
Patient 4 (915 U 18 007): dyskeratosis congenita 8 March 1994, ROR (9 May 1995 M
Skin biopsy 11 March 2010 Negative Negative
Patient 5 (915 U 18 008): unclassiﬁed combined immunodeﬁciency 30 June 1969, ROR (1970) F
Skin biopsy 1 April 2004 Negative Negative
Patient 6 (915 U 09 001): acquired immunodeﬁciency 24 January 1946, unknown
Skin biopsy (P3) 9 April 2013 Negative Negative
Healthy immunocompetent patient with normal skin
Patient 7 (915 U 18 005) 30 December 2008, Priorix
(30 September 2010; 8 October 2011
M
Skin biopsy 27 September 2012 Negative Negative
Patient 8 (915 U 18 006) 18 July 2008 F
Skin biopsy Priorix (3 August 2009;
8 October 2010)
27 September 2012 Negative Negative
F, female; M, male. *Index cases subjected to high-throughput sequencing analyses.
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RV detection by immunoﬂuorescence
Cryosections were labelled with a goat polyclonal antibody
against RV (20-RG04; Fitzgerald, Wicklow, Ireland), and then
with a secondary antibody coupled to Alexa-546. Slides were
counterstained with Hoechst (Vector Laboratories, Burlin-
game, CA, USA) and observed under an AxioObserver
microscope (Zeiss, Oberokochen, Germany). Pictures and
Z-stacks were obtained with AxioVision 4.5 software.
Results
A cutaneous granuloma biopsy sample (110292) from patient 1
was subjected to HTS, with the aim of identifying a potential
associated pathogen. Among a total of 80 million reads, four
contigs (149–240 bp; Fig. 2a) and 43 singletons (31–101 bp;
not shown) gave as best hits sequences of a known virus, the
Wistar 27/3 attenuated RV strain (FJ211588), which most
countries use as a live attenuated vaccine, and the ﬁve rubella
vaccine strains used in Japan (Matsuba.GMK3 (AB588189),
TCRB19 (AB588188), Matsuura (AB588191), TO-336.GMK5
(AB588192), and Takahashi (AB222608)). These contigs and
singletons showed a minimum of 98% and 96% nucleotide
identity, respectively, with the cited rubella vaccine strains. No
other viral read was found.
We next investigated patient 2. A skin biopsy sample
(120479) was sequenced with a greater depth (148 million
reads), and 21 contigs (102–584 bp; Fig. 2a) and 34 singletons
(32–101 bp; not shown) matched the rubella vaccine strains
mentioned above, with nucleotide identities ranging from 97%
to 100%. RV contigs covered approximately 46% of the
9762-bp reference genome of the Wistar 27/3 strain
(FJ211588) (Fig. 2a). Within the E1 window for rubella
genotyping recommended by the WHO, two contigs of
232 bp and 122 bp showed 99% and 100% identity with the
Wistar 27/3 vaccine strain. No other viral read was found.
RT-PCRs were performed with speciﬁc primers amplifying
more than the minimal 739 nucleotides of the E1 envelope
coding region, which is used for strain typing according to
WHO recommendations. For the biopsy samples of two
patients (110292 and 120479), the results were positive
(Table 1; Fig. 2b), and Sanger sequencing conﬁrmed the
presence of a genotype 1a virus that circulates neither in
France nor in most other countries, with a sequence very
close to that of the Wistar 27/3 vaccine strain FJ211588
(Tables S1 and S2; Figs S1, S2, and S4). RT-PCR was negative
for a biopsy sample of healthy skin of patient 2; the
corresponding control in patient 1 was not available.
Immunoﬂuorescence with an anti-RV polyclonal antibody
revealed the presence of RV antigens in cells of deep dermis
granuloma (Fig. 2) that were vimentin-positive (not shown).
The strain was also detected by RT-PCR for both patients in
granuloma biopsy samples obtained 4–5 years before and in
the lymphomatous lymph node biopsy sample of patient 1
obtained 4 months later (Table 1; Figs S3 and S5). Anti-RV
immunoﬂuorescence was negative on the RT-PCR-positive
lymphomatous lymph node (not shown). Concomitant plasma
and serum samples were negative (Table 1).
We next investigated the granuloma biopsy sample
(S-13-0089) of the third child with PID and granuloma,
referred to us in the course of this study. RT-PCR was
positive for the granuloma sample and negative for the healthy
skin. Sanger sequencing revealed the presence of a geno-
type 1a virus with a sequence very close to that of the
Wistar 27/3 vaccine strain FJ211588 (Table S3; Fig. S6).
As control, skin biopsy samples from three immunosup-
pressed and rubella-vaccinated patients with inﬂammatory
non-granuloma lesions (graft-versus-host disease, eczematous
lesions, and chronic chickenpox; patients 4, 5, and 6), and two
immunocompetent healthy children (patients 7 and 8) were
analysed for the presence of RV RNA. All were negative
(Table 1; Fig. 2b).
Discussion
We report here three cases of cutaneous granuloma
associated with rubella vaccine related-strains in patients
with PID. It is of note that these three cases were referred to
our centre consecutively, that their initial extensive micro-
biology work-up gave completely negative results, but that all
of them turned out to be positive for RV, suggesting a very
strong association between RV and skin granuloma in children
with PID. Granulomatous lesions are composed of inﬂamma-
tory cells, including macrophages. Granuloma may develop as
a response to a local trigger, leading to the activation of
macrophages that can show features of epithelioid and giant
cells, and T-lymphocytes. Granulomas develop as a result of
infectious or non-infectious antigenic triggers, whose persis-
tence favours granuloma development. This accounts for the
facts that: (i) pathogens associated with granulomas usually
cause chronic infection and persist within the host; and (ii)
conditions associated with continuous antigenic triggering and
a lack of antigen clearance lead to granuloma formation.
T-cell responses are important in granuloma formation, and
patients with deﬁcient T-cell functions are less likely to
develop granulomas [12], except those with eruptive granu-
loma annulare (GA) [13]. GA also occurs in immunocompe-
tent patients, in whom it shows a palisade aspect and is
usually non-eruptive. Members of the family Herpesviridae
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have been proposed as triggers in patients with eruptive GA
[14–16].
RV can be isolated from the skin during the acute phase of
rubella, even in the absence of rash [17]. RV persists in the skin
in congenital rubella, and this is attributed to a relatively high
tolerance to viral proteins expressed during fetal life [18].
We show here that RV has persisted for several years in
disseminated granulomas of unknown aetiology in all three
young patients with PID. The three virus strains are of
genotype 1a, and, although they are different from currently
circulating strains [11], they are closely related to the
Wistar 27/3 strain used in the vaccines from the two known
manufacturers, from which they were most likely derived,
subsequent to vaccination years before. The presence of RV
antigens was shown by immunoﬂuorescence (Fig. 2c), and
therefore they may well represent a persistent antigenic
(a)
(b)
(c)
i ii
FIG. 2. High-throughput sequencing, RT-PCR and immunoﬂuorescence of cutaneous granuloma biopsy samples. (a) Contigs identiﬁed by deep
sequencing in granuloma biopsy samples of patient 1 (110292) and patient 2 (120479) are shown, together with a genomic map of the strain
Wistar RA 27/3 (FJ211588). Each contig is represented by a horizontal bar together with the percentage of identity with the reference genome. For
clarity, singletons are not shown. (b) Results of RT-PCR with the primers 8669F and SPR8 are shown for (i) lesion (L) or healthy skin (H) biopsy
samples of the three index cases (patient (P)t1 to Pt3, with the corresponding year of sampling) and (ii) the ﬁve controls (Pt4 to Pt8). C: positive
control. M: 100-bp ladder. (c) Tissue sections of cutaneous granuloma frozen biopsy samples of patient 1 (left panel) and patient 2 (right panel)
immunolabelled with an anti-rubella polyclonal antibody and double-labelled with a secondary antibody coupled to Alexa-546. RV-positive cells
appear in red; nuclei are stained with Hoechst, and appear in blue. Fewer than one positive cell per ﬁeld and no cluster of positive cells were
observed. Control RV RT-PCR negative tissues were all RV-negative by immunoﬂuorescence. Bar: 10 lm.
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trigger that promoted granuloma formation. Although we
cannot deﬁnitely exclude a bystander effect for this skin-tropic
virus, its absence in healthy skin samples distant from
granuloma lesions and the serum of index cases rules out
widespread dissemination of RV in a context of immunode-
ﬁciency, and strongly supports a causal role for RV in
granuloma formation in paediatric PID. In support of this
hypothesis, RV was absent in control patients 4 and 5 with
immunodeﬁciency and non-granulomatous inﬂammatory skin
lesions, suggesting that RV is not detectable in all skin samples
of immunosuppressed patients, and is not a triggering factor
for such lesions.
It is of note that RV was also present in a lymphomatous
adenopathy in patient 1 but RV-expressing cells were not
identiﬁable by immunoﬂuorescence. Further investigations are
therefore needed to investigate a possible link between RV and
the development of lymphoma in this patient with AT, a
condition associated with a high risk of neoplasia, mainly
lymphoma. RV replicates in monocytes and also in activated
B-lymphocytes and T-lymphocytes [19,20]. Long-term viraemia
occurs in the context of congenital infection [21], and live
vaccine strains replicate in lymphocytes of immunocompetent
vaccinized individuals for several weeks [22]. RV capsid inhibits
Fas-dependent apoptosis mediated by Bax, and it has been
suggested that this may allow within-host viral dissemination
by way of apoptosis-resistant infected lymphocytes [23]. ATM
is one of the major kinases of the DNA damage response, and
Bax is also a component of the ATM signalling machinery in
some cell types [24], implying that ATM loss of function and
RV-associated Bax impairment could act synergistically to
avoid apoptosis, thereby favouring lymphoma development. In
addition, RV proteins may also act as a persistent antigenic
trigger that favours protracted lymphocyte activation and
accumulation of DNA damage. Lymphomas in AT patients
were described before the widespread use of rubella vaccines,
but the incidence of rubella was very high before vaccine
implementation, permitting a signiﬁcant exposure of AT
patient to RV [25].
Detection of the vaccine strain of RV in all three consecutive
cases strongly suggests a causal relationship between RV and
granuloma in patients with PID. Indeed, most of Hill’s criteria
[26] for causation are fulﬁlled: association, speciﬁcity, tempo-
rality (all these three patients were vaccinated before the
appearance of the granulomas, and RV persisted for years in the
lesions), and plausibility. A demonstration of causality will
nevertheless require multicentric prospective series of cases.
Our ﬁndings suggest that granulomas and lymphomas
occurring in the context of immunodeﬁciency should be
investigated for the presence of RV. The general population is
widely exposed to live rubella vaccine, including immunocom-
promised patients, and more particularly those with PID, who
are frequently unknowingly immunosuppressed at the time of
vaccination. It should be noted, however, that, in the absence
of widespread vaccination, patients with PID would probably
be exposed to non-attenuated RV, owing to circulating
wild-type RV.
This study has identiﬁed RV as a likely cause of cutaneous
granuloma in children with PID. It illustrates the strength of
deep sequencing in revealing the presence of unpredicted
infectious agents in patients’ tissue samples, and in uncovering
their putative role in poorly understood medical conditions.
The increasing use of HTS in clinics should be applied to
pathological tissue samples of patients with unknown medical
conditions, to search for associated infectious agents.
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